Evidence map›Paper›PMID 37380983›Full record

Trial reportCardiovascular diabetology2023

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin.

Pankaj Puar, Makoto Hibino, C David Mazer, Andrew T Yan, Arjun K Pandey, Adrian Quan, Hwee Teoh, David A Hess, Raj Verma, Kim A Connelly and 1 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Pankaj Puar *Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, 30 Bond Street, Toronto, ON, Canada.
Makoto Hibino *Department of Cardiac Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
C David MazerKeenan Research Centre for Biomedical Science in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.
Andrew T YanDivision of Cardiology, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada.
Arjun K PandeyMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Adrian QuanDivision of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, 30 Bond Street, Toronto, ON, Canada.
Hwee TeohDivision of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, 30 Bond Street, Toronto, ON, Canada.
David A HessDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Raj VermaRoyal College of Surgeons in Ireland, Dublin, Ireland.
Kim A ConnellyKeenan Research Centre for Biomedical Science in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.
Subodh VermaDivision of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, 30 Bond Street, Toronto, ON, Canada. Subodh.Verma@unityhealth.to.
St. Michael's Hospital · CAUniversity of Toronto · CAMcMaster University · CARoyal College of Surgeons in Ireland · IEUnity Health TorontoUniversity Hospitals of Cleveland · USWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a significant reduction in left ventricular mass indexed to body surface area (LVMi). In this sub-analysis, we evaluated whether baseline LVMi may influence how empagliflozin affects cardiac reverse remodelling.

methodsA total of 97 patients with type 2 diabetes and coronary artery disease were randomized to empagliflozin (10 mg/d) or matching placebo for 6 months. The study cohort was divided into those whose baseline LVMi was ≤ 60 g/m

resultsBaseline LVMi was 53.3 g/m

conclusionsPatients with higher LVMi at baseline experienced greater LVM regression with empagliflozin.

Indexed as

Coronary Artery DiseaseDiabetes Mellitus, Type 2Benzhydryl CompoundsGlucosidesHeartHumansBenzhydryl CompoundsempagliflozinGlucosidesCardiac reverse remodellingDiabetesHeart failureLeft ventricleSGLT2 inhibition

Identifiers

PMID37380983
PMCPMC10303338
OpenAlexW4382399784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.